Welcome!

News Feed Item

/ CORRECTION - Corcept Therapeutics

CHICAGO, IL -- (Marketwired) -- 06/20/14 -- In the news release, "New Research on Corcept's Korlym® for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014," issued Thursday, June 19, 2014 by Corcept Therapeutics (NASDAQ: CORT), we are advised by the company that the session schedule has now been updated to reflect accurate presentation times with poster numbers added. Complete corrected text follows.

New Research on Corcept's Korlym® for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014

New Data Includes Results of a Long-Term Extension Phase of Corcept's Multicenter, Open-Label SEISMIC Study

CHICAGO, IL -- Jun 19, 2014 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today announced that new clinical research on Korlym® (mifepristone) will be presented at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014).

The research, including results of a long-term extension phase of Corcept's multicenter, open-label SEISMIC study of Korlym, will be presented at the conference, taking place at the McCormick Place West Convention Center in Chicago from June 21-24. Korlym is a once-daily oral treatment for patients with Cushing's syndrome who have glucose intolerance and have failed or cannot have surgery.

"Cushing's syndrome, which is caused by excessive cortisol activity, is a serious condition that has a debilitating impact on all aspects of patients' lives. The disease often significantly affects patients' metabolism, leading to extreme weight gain with abnormal fat deposits, impaired glycemic control including type 2 diabetes, muscle weakness and, commonly, psychiatric symptoms," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "Because Cushing's syndrome may be a chronic disease, it is important to monitor patients taking Korlym over time. The long-term extension study of SEISMIC includes data from patients who had been receiving treatment for as long as 3.5 years."

Cushing's syndrome is the result of excessive cortisol activity throughout the body. Cortisol is a hormone made in the adrenal glands that performs vital tasks such as regulating the metabolism of proteins, carbohydrates and fats. Cushing's syndrome afflicts 20,000 people in the United States, with approximately 3,000 to 4,000 new cases each year. Approximately half of these patients are cured by surgery.

The following abstracts highlight new research on mifepristone:


----------------------------------------------------------------------------
Date      Session   Poster    Title                           Authors
          Time      Number
----------------------------------------------------------------------------
Saturday, 11:30am-  OR02-2    Late-Night Salivary Cortisol    Ty Brian
 June 21, 1:00pm              for the Diagnosis of Recurrent  Carroll, MD;
 2014                         Cushing's Disease: Evidence of  Bradley R
                              Clinical Benefit from Early     Javorsky, MD;
                              Detection                       James W
                                                              Findling, MD
          ------------------------------------------------------------------
          1:00-     SAT-0671  Clinical Management in a Female Elizabeth E
          3:00pm              with Persistent Cushing's       King, MD;
                              Disease Treated with            Simone M
                              Mifepristone for Four Years     Howell, RN,
                                                              CCRA
----------------------------------------------------------------------------
Sunday,   1:00-     SUN-0750  Effect of Mifepristone on       Vijay Babu
 June 22, 3:00pm              Cushing's syndrome Secondary to Balakrishnan;
 2014                         Bilateral Adrenal Adenomas: A   Pankaj Sharda,
                              Case Presentation               MBBS, MD;
                                                              Elias Said
                                                              Siraj, MD
----------------------------------------------------------------------------
Monday,   1:00-     MON-0439  Improved Activities of Daily    Daphne T
 June 23, 3:00pm              Living, Normal Mood and Quality Adelman, BSN,
 2014                         of Life: 4 Years of Treatment   MBA; Simone M
                              Data in a Premenopausal Woman   Howell, RN,
                              with Cushing's Disease          CCRA


                    --------------------------------------------------------
                    MON-0592  A Case Report of a 37 y/o Woman Howard A
                              Diagnosed with Cushing's        Brand, MD;
                              Disease Presenting As Pituitary Kimberly
                              Apoplexy after Multiple         Calcagno, MA;
                              Treatment Failures Effectively  Michele
                              Responds to Mifepristone        Lamerson, RN,
                                                              MS, CPNP
                    --------------------------------------------------------
                    MON-0595  Discontinuation of Insulin,     Kevin C.J.
                              Oral Antidiabetic and           Yuen, MD, FRCP
                              Antihypertensive Medications in (UK); Harold I
                              a Patient with Cushing's        Magazine, PhD
                              Disease Following Mifepristone
                              (MIFE) Therapy
                    --------------------------------------------------------
                    MON-0598  Mifepristone for Refractory     Audrey
                              Cushing's Syndrome in a Patient Elisabeth
                              with CKD Hyperkalemia           Arzamendi, MD;
                              Undergoing Surgical Exodontia   Alison Marie
                              and Weight Loss:                Semrad, DO
                              Recommendations for
                              Clinical/Biochemical Monitoring
                              and Perioperative Dosing
                    --------------------------------------------------------
                    MON-0663  Persistent Weight Loss in       Henry G. Fein,
                              Patients Treated with           MD; T. Brooks
                              Mifepristone (MIFE) for         Vaughan III,
                              Cushing's Syndrome: Results     MD; Coleman
                              from the Seismic & Long Term    Gross; Dat
                              Extension Studies               Nguyen
----------------------------------------------------------------------------

About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that regulate the effects of the stress hormone cortisol on the body. The FDA has approved the company's first drug, Korlym® (mifepristone) 300 mg Tablets, a glucocorticoid receptor antagonist, as a once-daily oral treatment for hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Corcept is exploring mifepristone (the active ingredient in Korlym) as a treatment for triple-negative breast cancer with a multi-center, Phase I clinical study currently underway in patients with metastatic or locally advanced unresectable breast cancer. It is also supporting investigator-led clinical studies of mifepristone in the treatment of ovarian cancer and castration-resistant prostate cancer. The company has a portfolio of selective glucocorticoid-receptor (GR) antagonists that block the effects of cortisol but not progesterone. It owns or has licensed extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic and psychiatric disorders and triple-negative breast cancer. It also holds composition of matter patents for its selective GR antagonists.

Investor Contact
Charles Robb
Corcept Therapeutics Incorporated
Chief Financial Officer
Email Contact
650-688-8783

Media Contact
Brian Baxter for Corcept
Lazar Partners Ltd.
Email Contact
646-871-8491

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
"Once customers get a year into their IoT deployments, they start to realize that they may have been shortsighted in the ways they built out their deployment and the key thing I see a lot of people looking at is - how can I take equipment data, pull it back in an IoT solution and show it in a dashboard," stated Dave McCarthy, Director of Products at Bsquare Corporation, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effici...
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
The cloud competition for database hosts is fierce. How do you evaluate a cloud provider for your database platform? In his session at 18th Cloud Expo, Chris Presley, a Solutions Architect at Pythian, gave users a checklist of considerations when choosing a provider. Chris Presley is a Solutions Architect at Pythian. He loves order – making him a premier Microsoft SQL Server expert. Not only has he programmed and administered SQL Server, but he has also shared his expertise and passion with b...
"IoT is going to be a huge industry with a lot of value for end users, for industries, for consumers, for manufacturers. How can we use cloud to effectively manage IoT applications," stated Ian Khan, Innovation & Marketing Manager at Solgeniakhela, in this SYS-CON.tv interview at @ThingsExpo, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
The cloud promises new levels of agility and cost-savings for Big Data, data warehousing and analytics. But it’s challenging to understand all the options – from IaaS and PaaS to newer services like HaaS (Hadoop as a Service) and BDaaS (Big Data as a Service). In her session at @BigDataExpo at @ThingsExpo, Hannah Smalltree, a director at Cazena, provided an educational overview of emerging “as-a-service” options for Big Data in the cloud. This is critical background for IT and data professionals...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has been named the Number One Brand in the “M2M 2016: Top 100 Influencers and Brands” by Onalytica. Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M OR “Machine to Machine.” They then identified the top 100 most influential brands and individuals leading the discussion on Twitter.
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...